Cue Biopharma, Inc. CUE

Cue Biopharma Inc es una empresa de inmunoterapia en etapa de desarrollo. La empresa se enfoca en el desarrollo de biológicos diseñados para modular selectivamente subconjuntos de células T relevantes para tratar el cáncer y enfermedades autoinmunes. Su cartera de Inmunoterapia Oncológica incluye el Marco CUE-100 y el Marco CUE-200; y la cartera de enfermedades autoinmunes incluye el Programa de Clase I de MHC y el Programa de Clase II de MHC. El Marco CUE-100 restringe la actividad de las poblaciones de células T. El Marco CUE-200 permite respuestas potentes y duraderas de células T antitumorales. La terapia para enfermedades autoinmunes protege a las células sanas del ataque inmune.

CUE hizo una agrupación de acciones (split inverso) de 1:30 el 24 de abril de 2026: cada 30 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 30 sept

  Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

  The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

  

• GlobeNewswire Inc. 23 sept

  Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer

  Lift Therapeutics announced the appointment of Daniel Passeri as CEO, bringing over 30 years of oncology drug development experience. Bo Rode Hansen transitions from Interim CEO to President and Board member. The company is preparing to advance its lead immuno-Modulatory Alpha Neutrophil (iMAN) program into first-in-human clinical studies in early 2027.

  

• GlobeNewswire Inc. 13 jul

  Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

  The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

  

• GlobeNewswire Inc. 9 jul

  Cue Biopharma Announces $50.0 Million Private Placement

  Cue Biopharma secured $50 million in funding through a private placement led by Cormorant Asset Management and Columbia Threadneedle Investments. The company will use proceeds to advance clinical development of its immunological disorder therapies, including Phase 2 data expected from a CSU study in China by Q3 2026.